Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,232 stopped studies mapped to B-Cell Malignant Neoplasm and descendants · 88% state a reason
Over the 1,232 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03103971 | huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell… | Phase 1 | terminated | Apr 7, 2017 | Fred Hutchinson Cancer Center | Terminated due to slow enrollment and end of funding | Enrollment / accrual |
| NCT05465876 | Passive Antibodies Against COVID-19 With EVUSHELD in Vaccine Non-responsive CLL(PACE-CLL) | Phase 2 | withdrawn | Jul 20, 2022 | Sunnybrook Health Sciences Centre | Funding pulled | Funding |
| NCT05013437 | Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT…(AHCT) | Early Phase 1 | withdrawn | Aug 19, 2021 | Koen van Besien | The original principal Investigator left the institution. | Investigator |
| NCT03288493 | P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM) | Phase 1 / Phase 2 | terminated | Sep 20, 2017 | Poseida Therapeutics, Inc. | Phase I portion of the study was completed. The phase II portion of the study was terminated early… | Other (stated, no rule matched) |
| NCT04762160 | SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects… | Phase 2 | terminated | Feb 21, 2021 | Epizyme, Inc. | Decision to terminate EZH-1401 was solely due to company business decision. | Sponsor / business decision |
| NCT03571828 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in… | Phase 1 | terminated | Jun 28, 2018 | Amgen | Amgen decided to discontinue study because of a business decision and not because of safety reasons | Safety / toxicity |
| NCT04115059 | Dasatinib In Waldenström Macroglobulinemia | Phase 1 | terminated | Oct 3, 2019 | Jorge J. Castillo, MD | Lack of efficacy | Efficacy / futility |
| NCT04083898 | Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma | Phase 1 | terminated | Sep 10, 2019 | Washington University School of Medicine | Decision made to not move forward with Phase II portion of trial | Other (stated, no rule matched) |
| NCT03098355 | Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell… | Phase 1 / Phase 2 | withdrawn | Mar 31, 2017 | Zhujiang Hospital | The company did not offer the appropriate CART services. | Sponsor / business decision |
| NCT05613348 | CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma(CAR19T2) | Phase 1 / Phase 2 | withdrawn | Nov 14, 2022 | Zhujiang Hospital | The company failed to provide corresponding CART services. | Sponsor / business decision |
| NCT03473496 | CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma(MM) | N/A | terminated | Mar 22, 2018 | Zhujiang Hospital | After CAR-T treatment, the benefit is not significant, and it is difficult to enroll. | Enrollment / accrual |
| NCT02451111 | Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma | Phase 2 | terminated | May 21, 2015 | Swiss Cancer Institute | The premature termination is based on the decision by the SAKK board on November 14, 2020 due to… | Funding |
| NCT02700841 | Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation | Phase 2 | terminated | Mar 7, 2016 | University of Nebraska | Study terminated prematurely due to poor recruitment. | Enrollment / accrual |
| NCT03151057 | Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived… | Phase 1 | terminated | May 12, 2017 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Safety endpointreached | Safety / toxicity |
| NCT03982992 | Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab(DLI-TARGET) | Phase 2 | withdrawn | Jun 12, 2019 | Ludwig-Maximilians - University of Munich | Lack of potential study subjects due to a change of standard of care treatment outside of clinical… | Other (stated, no rule matched) |
| NCT06160609 | Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40… | Phase 1 / Phase 2 | terminated | Dec 7, 2023 | GlaxoSmithKline | The study was terminated due to lack of efficacy. | Efficacy / futility |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME… | Phase 1 | terminated | Mar 18, 2019 | OHSU Knight Cancer Institute | Low accrual | Enrollment / accrual |
| NCT05796271 | Clinical Trial of Roflumilast Added to Standard Chemoimmunotherapy | Phase 1 | withdrawn | Apr 3, 2023 | The University of Texas Health Science Center at San Antonio | Inadequate funding to begin enrolling subjects | Enrollment / accrual |
| NCT06247540 | Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's… | Phase 2 | withdrawn | Feb 8, 2024 | Northwestern University | Funding | Funding |
| NCT05611853 | Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell… | Phase 1 / Phase 2 | terminated | Nov 10, 2022 | BioNova Pharmaceuticals (Shanghai) LTD. | Due to company decision | Sponsor / business decision |
| NCT05641324 | A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With… | Phase 1 | terminated | Dec 7, 2022 | Anaveon AG | The study was ended due to a lack of recruitment | Enrollment / accrual |
| NCT04912427 | Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe… | Phase 1 | terminated | Jun 3, 2021 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT03684694 | Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell… | Phase 1 / Phase 2 | terminated | Sep 26, 2018 | ADC Therapeutics S.A. | Administrative decision | Other (stated, no rule matched) |
| NCT04466475 | Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell… | Phase 1 | withdrawn | Jul 10, 2020 | Fred Hutchinson Cancer Center | NIH terminated funding. Study was closed before any participants were enrolled. | Enrollment / accrual |
| NCT05107856 | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or… | Phase 1 | terminated | Nov 4, 2021 | Prelude Therapeutics | Company Decision | Sponsor / business decision |
| NCT03151811 | A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients…(OCEAN) | Phase 3 | terminated | May 12, 2017 | Oncopeptides AB | Sponsor assessed all endpoints and collected Overall Survival data for another two years following… | Other (stated, no rule matched) |
| NCT01769222 | Ipilimumab and Local Radiation for Selected Solid Tumors | Phase 1 | terminated | Jan 16, 2013 | Stanford University | Planned Future Study | Other (stated, no rule matched) |
| NCT04025216 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | Phase 1 | terminated | Jul 18, 2019 | Kite, A Gilead Company | The sponsor finds the risk/benefit analysis unfavorable and has terminated the study. | Other (stated, no rule matched) |
| NCT04465760 | Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer… | Phase 2 | terminated | Jul 10, 2020 | OHSU Knight Cancer Institute | Insufficient accrual rate | Enrollment / accrual |
| NCT04505813 | Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma | Phase 1 / Phase 2 | suspended | Aug 10, 2020 | NexImmune Inc. | Lack of accrual | Enrollment / accrual |
| NCT04220008 | Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the… | Phase 2 | withdrawn | Jan 7, 2020 | M.D. Anderson Cancer Center | No Participants Enrolled | Enrollment / accrual |
| NCT03502577 | BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat… | Phase 1 | terminated | Apr 18, 2018 | Fred Hutchinson Cancer Center | Closed per SRC Low Accrual Policy | Enrollment / accrual |
| NCT03657251 | MMRF CureCloud Research Initiative | — | terminated | Sep 5, 2018 | Multiple Myeloma Research Foundation | The MMRF has learned of the limitations of using a blood sample to collect genomic data, compared… | Other (stated, no rule matched) |
| NCT03864419 | Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell… | Phase 1 | terminated | Mar 6, 2019 | Fred Hutchinson Cancer Center | Closed per SRC Low Accrual Policy | Enrollment / accrual |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | Phase 1 | terminated | Dec 5, 2019 | University of Florida | Sponsor terminated | Other (stated, no rule matched) |
| NCT05980507 | An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201… | Phase 1 | withdrawn | Aug 8, 2023 | The First Affiliated Hospital of Soochow University | Molecular development strategy adjustment | Sponsor / business decision |
| NCT04549363 | Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab… | Phase 3 | terminated | Sep 16, 2020 | GlaxoSmithKline | The study has been terminated for reasons pertaining to feasibility | Other (stated, no rule matched) |
| NCT04828174 | Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies | Phase 1 | suspended | Apr 1, 2021 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | The trial was suspended due to the inability to enroll qualified participants | Enrollment / accrual |
| NCT04864522 | Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma(MM FPBMC) | Phase 1 / Phase 2 | withdrawn | Apr 29, 2021 | University of Virginia | Slow accrual due to a crowded field of effective drugs by the time the study opened | Enrollment / accrual |
| NCT04978779 | A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic… | Phase 1 | terminated | Jul 27, 2021 | Vincerx Pharma, Inc. | Slow enrollment | Enrollment / accrual |
| NCT05647512 | Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other… | Phase 1 / Phase 2 | withdrawn | Dec 12, 2022 | LaNova Medicines Limited | According to sponsor strategy | Sponsor / business decision |
| NCT05321862 | Relevance Evaluation of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal…(PENTI-MIDAS) | Phase 2 | withdrawn | Apr 11, 2022 | Nantes University Hospital | MIDAS inclusions terminated before first inclusion in PENTI-MIDAS | Other (stated, no rule matched) |
| NCT05929716 | An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as… | Phase 2 | withdrawn | Jul 3, 2023 | M.D. Anderson Cancer Center | Per Principal Investigator request | Investigator |
| NCT03572634 | Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously… | Phase 1 / Phase 2 | terminated | Jun 28, 2018 | Sumitomo Pharma America, Inc. | Given the extensive time projected to conclude the study hypothesis, it is no longer feasible to… | Other (stated, no rule matched) |
| NCT02188368 | Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients | Phase 2 | terminated | Jul 11, 2014 | Oncotherapeutics | Lack of enrollment | Enrollment / accrual |
| NCT02294357 | Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2… | Phase 2 | terminated | Nov 19, 2014 | Oncotherapeutics | Early termination due to the difficulties to enroll subjects. | Enrollment / accrual |
| NCT05222438 | Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant | Phase 2 | withdrawn | Feb 3, 2022 | Barbara Ann Karmanos Cancer Institute | No accrual of participants in 18 months | Enrollment / accrual |
| NCT04023071 | FT516 in Subjects With Advanced Hematologic Malignancies | Phase 1 | terminated | Jul 17, 2019 | Fate Therapeutics | The study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT04245722 | FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies | Phase 1 | terminated | Jan 29, 2020 | Fate Therapeutics | The study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT03733691 | Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients | Phase 2 | terminated | Nov 7, 2018 | Oncotherapeutics | Insufficient enrollment | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Apr 10, 2024source: clinicaltrials